Search

Your search keyword '"Miller NL"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Miller NL" Remove constraint Author: "Miller NL" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
21 results on '"Miller NL"'

Search Results

2. Prostate MRI Transitional Zone Volume Predicts BPH Enucleation Volume Better than Alternative Modalities.

4. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.

5. Nonopioid Pain Management Pathways for Stone Disease.

6. Acute Renal Failure with Severe Loin Pain and Patchy Renal Ischemia after Anaerobic Exercise in Active Duty Marines.

7. Factors Affecting Holmium Laser Efficiency: Comparison of Laryngeal Mask Airway and Endotracheal Intubation During Ureteroscopy for Renal Stones.

8. Quick Sequential Organ Failure Assessment Score Is a Better Predictor of Septic Shock After Percutaneous Nephrolithotomy: A Secondary Analysis of Two Multicenter Prospective Trials.

9. The Fate of Residual Fragments After Percutaneous Nephrolithotomy: Results from the Endourologic Disease Group for Excellence Research Consortium.

11. Association between obstructive sleep apnea and 24-h urine chemistry risk factors for urinary stone disease.

12. Kidney Stone Prevalence Based on Self-Report and Electronic Health Records: Insight into the Prevalence of Active Medical Care for Kidney Stones.

13. Learned features of antibody-antigen binding affinity.

14. Prospective randomized trial of 2 versus 12-weeks of postoperative antibiotics after percutaneous nephrolithotomy in complex patients with infection-related kidney stones.

15. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.

16. Proton pump inhibitors use and risk of incident nephrolithiasis.

17. Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies.

18. A structural dynamic explanation for observed escape of SARS-CoV-2 BA.2 variant mutation S371L/F.

19. Conserved topology of virus glycoepitopes presents novel targets for repurposing HIV antibody 2G12.

20. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain.

21. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant.

Catalog

Books, media, physical & digital resources